PC
DFTX

Pier Capital’s Definium Therapeutics DFTX Stock Holding History

Pier Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.17M Buy
+88,598
New +$2.19M 0.55% 85

Other funds holding DFTX

AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PFA
Peak Financial Advisors Denver, Colorado $242M AUM 19.63% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Pier Capital's DFTX Position: Q2 2026 in Review

Pier Capital opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 88,598 shares worth $4.17M. The stake represents 0.55% of the portfolio and ranks #85 among its holdings.

102 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Pier Capital held 88,598 shares of Definium Therapeutics worth $4.17M as of Q2 2026.
  • Definium Therapeutics was a new Pier Capital position in Q2 2026.
  • Definium Therapeutics made up 0.55% of Pier Capital's portfolio in Q2 2026, its #85 holding.
  • 102 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Pier Capital's 13F filing for Q2 2026, filed 5 Aug 2026.